ms and semaglutide In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than over 72 weeks, nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms .spr.ly/6183SkuIL Pharmacokinetics and weight loss effects

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

The UK Association of Anaesthetists published comprehensive multidisciplinary consensus in January 2025, recommending that GLP-1 receptor agonists be continued before surgery with individualised risk assessment [42]

Refreezing is discouraged

Improved Blood Sugar Control Approved by the FDA for the treatment of type-2 diabetes, semaglutide increases insulin production and decreases the amount of sugar released by the liver

Drink plenty of fluids to increase intestinal motility